real-time news and commentary for investors
Tuesday, Sep 10
Oxygen Biotherapeutics jumps on issuance of patent for its treatment of pruritus
- Oxygen Biotherapeutics (OXBT +20%) pops after the USPTO issued the drug developer a patent earlier today for its treatment for pruritus - a sensation patients instinctually try to relieve by rubbing or scratching.
- The company says it's currently evaluating commercialization strategies, which potentially includes out-licensing for conditions such as allergic contact dermatitis, psoriasis and acne.